Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + pegylated interferon alfa-2a
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Atezolizumab + pegylated interferon alfa-2a is a combination of two distinct immunotherapeutic agents: atezolizumab, a monoclonal antibody that blocks the programmed death-ligand 1 (PD-L1) pathway to enhance anti-tumor immune responses, and pegylated interferon alfa-2a, a pegylated cytokine that stimulates the innate and adaptive immune system through activation of type 1 interferon receptors and the JAK/STAT pathway. This combination has been investigated primarily in advanced solid tumors, especially renal cell carcinoma, aiming to augment endogenous anti-tumor immunity. Clinical trials have primarily evaluated safety and tolerability, with preliminary results showing that the regimen is generally well tolerated, though the added efficacy compared to established regimens appears limited. The drugs are developed by Genentech (atezolizumab) and Roche (pegylated interferon alfa-2a)[1][3][4].
- Other names
- atezolizumab plus pegylated interferon alfa-2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)CD274 (Programmed cell death protein 1 ligand 1)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on atezolizumab + pegylated interferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + pegylated interferon alfa-2a.